Compare Pfizer Inc (PFE) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance

Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.

Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.

SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.

The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.